Date Title Description PDF
23 Feb 2022 On business and financial situation The Company releases the press release related to the full year 2021 financial results Download
23 Feb 2022 On business and financial situation The Company releases the full year 2021 financial results presentation Download
23 Feb 2022 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
22 Feb 2022 On buy-back programmes ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022.     Download
16 Feb 2022 On business and financial situation Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years       Download

Pages

Date Title Description PDF
02 Feb 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 26 January and 1 February 2024 Download
26 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 19 January and 25 January 2024 Download
19 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 12 January and 18 January 2024 Download
12 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 5 January and 11 January 2024 Download
05 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 29 December 2023 and 4 January 2024 Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages